Simcere Zaiming announced the second BD partnership from its TCE platform.
Published
Signal category
Partnerships
Quote
“The second BD partnership from our TCE platform”
— Frank Luo|Simcere Zaiming team
Company
Simcere Zaiming
Providing today's cancer patients with medicines of the future
- Industry
- Pharmaceutical Manufacturing
- Location
- 南京, CN
- Company size
- 51 employees
Simcere Zaiming is an oncology-focused bipharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Limited . Founded in 2023, Simcere Zaiming is dedicated to developing ground breaking therapies to meet the unmet clinical needs of cancer patients globally. With a robust and innovative R&D pipeline featuring distinct clinical assets, Simcere Zaiming has successfully launched several innovative products in China, including Enzeshu, COSELA, Enweida, Endosta, and Enlituo. The company is determined to deliver potentially transformative treatment options to cancer patients worldwide through its R&D, manufacturing, and commercialization capabilities, complemented by strategic collaborations with leading partners.pr@zaiming.com
Founded 2023